The Sarepta Therapeutics Inc. to Post FY2020 Earnings of $2.37 Per Share, Wedbush Forecasts (SRPT)

The Sarepta Therapeutics Inc. to Post FY2020 Earnings of $2.37 Per Share, Wedbush Forecasts (SRPT)

Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Wedbush increased their FY2020 earnings estimates for shares of Sarepta Therapeutics in a research report issued on Monday. Wedbush analyst H. Behanna now expects that the firm will earn $2.37 per share for the year, up from their prior forecast of $2.33. Wedbush has a “Outperform” rating and a $72.00 price target on the stock.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter in the prior year, the company earned ($0.87) earnings per share.

Other research analysts also recently issued research reports about the company. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a report on Sunday, July 17th. Jefferies Group set a $58.00 price objective on Sarepta Therapeutics and gave the company a “hold” rating in a report on Sunday, October 2nd. William Blair raised Sarepta Therapeutics from a “market perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research report on Monday, September 19th. Piper Jaffray Cos. raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Monday, September 19th. Finally, Needham & Company LLC upped their target price on Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, July 22nd. One research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $58.44.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 1.08% during midday trading on Tuesday, reaching $54.19. The company had a trading volume of 1,781,797 shares. Sarepta Therapeutics has a 52 week low of $8.00 and a 52 week high of $63.73. The company’s market capitalization is $2.60 billion. The company’s 50 day moving average price is $43.47 and its 200-day moving average price is $26.16.

Several institutional investors have recently bought and sold shares of SRPT. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock worth $59,227,000 after buying an additional 161,790 shares during the period. State Street Corp increased its position in Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock worth $58,976,000 after buying an additional 625,051 shares during the period. BlackRock Fund Advisors increased its position in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock worth $20,865,000 after buying an additional 25,799 shares during the period. Finally, Franklin Resources Inc. bought a new position in Sarepta Therapeutics during the first quarter worth $13,506,000. 65.29% of the stock is currently owned by institutional investors and hedge funds.

In other Sarepta Therapeutics news, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the sale, the chief executive officer now directly owns 76,983 shares of the company’s stock, valued at approximately $2,309,490. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Edward M. Md Kaye sold 24,352 shares of the business’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,217,600.00. Following the sale, the chief executive officer now directly owns 89,983 shares in the company, valued at $4,499,150. The disclosure for this sale can be found here. Company insiders own 10.90% of the company’s stock.

About Sarepta Therapeutics

Related posts

Leave a Comment